FOX proteins are a superfamily of transcription factors which share a DNA-binding domain referred to as the forkhead domain. Our focus is on the FOXP subfamily members, which are involved in language and cognition amongst other things. The FOXP proteins contain a conserved zinc finger and a leucine zipper motif in addition to the forkhead domain. The remainder of the sequence is predicted to be unstructured and includes an acidic C-terminal tail. In the present study, we aim to investigate how both the structured and unstructured regions of the sequence cooperate so as to enable FOXP proteins to perform their function. We do this by studying the effect of these regions on both oligomerisation and DNA binding. Structurally, the FOXP proteins appear to be comparatively globular with a high proportion of helical structure. The proteins multimerise via the leucine zipper, and the stability of the multimers is controlled by the unstructured interlinking sequence including the acid rich tail. FOXP2 is more compact than FOXP1, has a greater propensity to form higher order oligomers, and binds DNA with stronger affinity. We conclude that while the forkhead domain is necessary for DNA binding, the affinity of the binding event is attributable to the leucine zipper, and the unstructured regions play a significant role in the specificity of binding. The acid rich tail forms specific contacts with the forkhead domain which may influence oligomerisation and DNA binding, and therefore the acid rich tail may play an important regulatory role in FOXP transcription.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789814 | PMC |
http://dx.doi.org/10.1042/BSR20202128 | DOI Listing |
PeerJ
December 2024
Department of Gynecology, Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Background: Immunogenic cell death (ICD) has been associated with enhanced anti-tumor immunotherapy by stimulating adaptive immune responses and remodeling the immune microenvironment in tumors. Nevertheless, the role of ICD-related genes in ovarian cancer (OC) and tumor microenvironment remains unexplored.
Methods: In this study, high-throughput transcriptomic data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases as training and validation sets separately were obtained and proceeded to explore ICD-related clusters, and an ICD-related risk signature was conducted based on the least absolute shrinkage and selection operator (LASSO) Cox regression model by iteration.
Urol Oncol
December 2024
Mardin Training and Research Hospital, Pathology Laboratory, Mardin, Turkey. Electronic address:
Open Biol
December 2024
Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Approximately 10-15% of human cancers are telomerase-negative and maintain their telomeres through a recombination-based process known as the alternative lengthening of telomeres (ALT) pathway. Loss of the alpha-thalassemia/mental retardation, X-linked (ATRX) chromatin remodeller is a common event in ALT-positive cancers, but is generally insufficient to drive ALT induction in isolation. We previously demonstrated that ATRX binds to the MRN complex, which is also known to be important in the ALT pathway, but the molecular basis of this interaction remained elusive.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
Department of Clinical Laboratory, Peking University People's Hospital, Beijing, China. Electronic address:
Objective: This study aimed to investigate the role of CD55 in regulatory T cells (Tregs) and clarify its clinical relevance in rheumatoid arthritis (RA).
Methods: Flow cytometry was used to examine the expression of Helios and CTLA-4 in CD55 + and CD55- Tregs in mouse peripheral blood and spleen. FoxP3 mice were employed to analyze the in vitro inhibitory function of CD55 + and CD55-Tregs.
Blood Adv
December 2024
Case Western Reserve University, Cleveland, Ohio, United States.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!